Research & Development
Dr. Reddy's Launches Generic Version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the US Market
8 April 2021 - - Indian drugmaker Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY) has launched Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg, a therapeutic equivalent generic version of Kuvan (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, USP, approved by the US Food and Drug Administration (USFDA), the company said.

Dr. Reddy's Sapropterin Dihydrochloride Powder for Oral Solution, is available in 100 mg unit dose packets in a 30 count carton.

Dr. Reddy's Laboratories is an integrated pharmaceutical company whose three businesses include Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products.

The company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Its major markets include USA, India, Russia and CIS countries, and Europe.
Login
Username:

Password:


Related Headlines